300 related articles for article (PubMed ID: 15976338)
1. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.
Sahni D; Robson A; Orchard G; Szydlo R; Evans AV; Russell-Jones R
J Clin Pathol; 2005 Jul; 58(7):715-21. PubMed ID: 15976338
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.
Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B
J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642
[TBL] [Abstract][Full Text] [Related]
3. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
Massi D; Puig S; Franchi A; Malvehy J; Vidal-Sicart S; González-Cao M; Baroni G; Ketabchi S; Palou J; Santucci M
J Clin Pathol; 2006 Feb; 59(2):166-73. PubMed ID: 16443733
[TBL] [Abstract][Full Text] [Related]
4. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
5. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?
Heindl LM; Hofmann TN; Adler W; Knorr HL; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
Ophthalmology; 2010 Feb; 117(2):334-42. PubMed ID: 19892405
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
[TBL] [Abstract][Full Text] [Related]
7. Intraocular lymphatics in ciliary body melanomas with extraocular extension: functional for lymphatic spread?
Heindl LM; Hofmann TN; Schrödl F; Holbach LM; Kruse FE; Cursiefen C
Arch Ophthalmol; 2010 Aug; 128(8):1001-8. PubMed ID: 20697000
[TBL] [Abstract][Full Text] [Related]
8. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension.
Heindl LM; Hofmann TN; Knorr HL; Rummelt C; Schrödl F; Schlötzer-Schrehardt U; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
Invest Ophthalmol Vis Sci; 2009 May; 50(5):1988-95. PubMed ID: 19151383
[TBL] [Abstract][Full Text] [Related]
9. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
[TBL] [Abstract][Full Text] [Related]
10. Investigation of intratumoural and peritumoural lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours.
Ji RC; Eshita Y; Kato S
Int J Exp Pathol; 2007 Aug; 88(4):257-70. PubMed ID: 17696907
[TBL] [Abstract][Full Text] [Related]
11. No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load.
Bogenrieder T; van Dijk MR; Blokx WA; Ramrath K; Seldenrijk K; Stolz W; van Diest PJ
Histopathology; 2011 Aug; 59(2):318-26. PubMed ID: 21884211
[TBL] [Abstract][Full Text] [Related]
12. Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis.
Shayan R; Karnezis T; Murali R; Wilmott JS; Ashton MW; Taylor GI; Thompson JF; Hersey P; Achen MG; Scolyer RA; Stacker SA
Histopathology; 2012 Oct; 61(4):702-10. PubMed ID: 22734806
[TBL] [Abstract][Full Text] [Related]
13. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy.
Pearl RA; Pacifico MD; Richman PI; Wilson GD; Grover R
J Plast Reconstr Aesthet Surg; 2008; 61(3):265-71. PubMed ID: 17569608
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva.
Heindl LM; Hofmann-Rummelt C; Adler W; Bosch JJ; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
Ophthalmology; 2011 Dec; 118(12):2351-60. PubMed ID: 21835473
[TBL] [Abstract][Full Text] [Related]
15. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
16. Tumor lymphangiogenesis and melanoma metastasis.
Rinderknecht M; Detmar M
J Cell Physiol; 2008 Aug; 216(2):347-54. PubMed ID: 18481261
[TBL] [Abstract][Full Text] [Related]
17. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours.
Cochran AJ; Roberts A; Wen DR; Huang RR; Itakura E; Luo F; Binder SW
Pathology; 2004 Oct; 36(5):478-84. PubMed ID: 15370119
[TBL] [Abstract][Full Text] [Related]
18. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
19. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node.
Davids V; Kidson SH; Hanekom GS
Melanoma Res; 2003 Jun; 13(3):313-24. PubMed ID: 12777989
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis after sentinel node biopsy in malignant melanoma].
Lock-Andersen J; Horn J; Sjøstrand H
Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
